- Iovance Biotherapeutics to Present at Upcoming Conferences and Events
- Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
- Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024
- Iovance Biotherapeutics to Present at Upcoming Conferences
- Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
- Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
- Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
- Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024
More ▼
Key statistics
As of last trade, Iovance Biotherapeutics Inc (2LB:MUN) traded at 8.33, 163.94% above the 52 week low of 3.16 set on Oct 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.33 |
---|---|
High | 8.33 |
Low | 8.33 |
Bid | 7.87 |
Offer | 7.93 |
Previous close | 8.42 |
Average volume | 1.01k |
---|---|
Shares outstanding | 279.83m |
Free float | 259.05m |
P/E (TTM) | -- |
Market cap | 2.48bn USD |
EPS (TTM) | -1.82 USD |
Data delayed at least 15 minutes, as of Jun 03 2024 07:16 BST.
More ▼